Biomedical subjects

Garnet Anderson

Publications and source records attributed to Garnet Anderson.

3 recordsLinked to original sources

PubMed2003

Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative.

We analyzed data from the prospective Women's Health Initiative (WHI) Observational Study to examine the effects of regular use of aspirin, ibuprofen, and other nonsteroidal anti-inflammatory drugs (NSAIDs) on breast cancer risk. We studied a population of 80,741 postmenopausal women between 50 and 79 years of age who reported no history of breast cancer or other cancers (excluding nonmelanoma skin cancer), and we completed a personal baseline interview that elicited comprehensive health information including data on breast cancer risk factors and NSAID use. All of the cases were adjudicated by WHI physicians using pathology reports. Our analysis was based on 1392 confirmed cases of breast cancer. Relative risks (RRs) with 95% confidence intervals (CIs) were estimated with adjustment for age and other breast cancer risk factors. Regular NSAID use (two or more tablets/week) for 5-9 years produced a 21% reduction in the incidence of breast cancer (RR, 0.79; 95% CI, 0.60-1.04); regular NSAID use for 10 or more years produced a 28% reduction (RR, 0.72; CI, 0.56-0.91), and there was a statistically significant inverse linear trend of breast cancer incidence with the duration of NSAID use (P < 0.01). The estimated risk reduction for long-term use of ibuprofen (RR, 0.51; CI, 0.28-0.96) was greater than for aspirin (RR, 0.79; CI, 0.60-1.03). Subgroup analysis by breast cancer risk factors did not result in effect modification. Regular use of acetaminophen (an analgesic agent with little or no anti-inflammatory activity) or low-dose aspirin (<100 mg) was unrelated to the incidence of breast cancer. Our results indicate that the regular use of aspirin, ibuprofen, or other NSAIDs may have a significant chemopreventive effect against the development of breast cancer and underscore the need for clinical trials to confirm this effect.

Age Factors↗

PubMed2003

Antioxidant supplement use in Women's Health Initiative participants.

BACKGROUND: Although antioxidant supplements are widely available and commonly used in the United States, there is a lack of detailed information on their use, including types of supplements used, doses, duration of use, and changes in use over time. METHODS: Antioxidant supplement use was assessed in participants in the Clinical Trial (n = 68,133) and Observational Study (n = 93,676) of the Women's Health Initiative. In-person interviews and a computerized inventory procedure were used to collect data on supplement use during baseline clinic visits from 1993 through 1998. RESULTS: Antioxidant supplements were widely consumed. For example, 55.5% of participants reported taking supplemental vitamin C in some form. Supplement use was positively associated with age, education, and physical activity. Most antioxidants were consumed through multivitamins. However, high doses were commonly consumed from single supplements, with 43.9% using single vitamin C supplements taking >500 mg and 86.1% using single vitamin E supplements taking >200 IU daily. Except for beta-carotene, there were increases in the use of all supplements from 1993 to 1998. CONCLUSIONS: This report demonstrates the feasibility of collecting comprehensive dietary supplement use data in large studies. These data may aid in the design of supplement use questionnaires, which could help to prevent misclassification error in epidemiologic studies of diet and disease.

Adult↗

PubMed2003

The case for early detection.

Early detection represents one of the most promising approaches to reducing the growing cancer burden. It already has a key role in the management of cervical and breast cancer, and is likely to become more important in the control of colorectal, prostate and lung cancer. Early-detection research has recently been revitalized by the advent of novel molecular technologies that can identify cellular changes at the level of the genome or proteome, but how can we harness these new technologies to develop effective and practical screening tests?

Biomarkers, Tumor↗